alectinib
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
alectinib
Jul 20, 2024, 17:56 |
Blog
Oncology Brothers: Lung Series with Balazs Halmos
Oncology Brothers shared a post on X: "Lung Series: with Balazs Halmos we discussed the SoC for…
Jun 16, 2024, 17:20 |
Insight
Yvonne Diaz: EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer
Yvonne Diaz, Co-founder of Oncogene Cancer Research, shared a post on X: “Great to see that…
Jun 8, 2024, 16:06 |
Blog
Reflections on ASCO24 by Jill Feldman
Jill Feldman shared on X/Twitter: "1. What an honor to meet Dr. Lynn Schuchter. I'm grateful…
Apr 30, 2024, 07:31 |
Insight
Top 5 posts of the week by Cancer Network
Cancer Network shared on their X/Twitter page: "View our top 5 posts of the week:…
Apr 26, 2024, 10:07 |
Drugs
Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer
Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter: ''HOT OFF…
Apr 23, 2024, 10:44 |
Blog
Ben Solomon: A timely discussion with Narjust Florez about the ALINA trial
Ben Solomon, Lung Cancer Medical Oncologist at Peter MacCallum Cancer Centre, shared a post by…
Apr 19, 2024, 15:52 |
Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Apr 15, 2024, 13:28 |
Insight
Antonio Passaro: Release of our editorial, co-authored with Peters Solange, focusing on the groundbreaking ALINA study
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on LinkedIn: ''I am thrilled…
Apr 15, 2024, 01:09 |
Blog
Antonio Passaro: Our editorial on the groundbreaking ALINA trial
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on X/Twitter: "Just published in…
Apr 14, 2024, 22:26 |
Insight
Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared a post on LinkedIn:…
Apr 13, 2024, 09:40 |
Drugs
Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC
Rami Manochakian, thoracic medical oncologist at Mayo Clinic, shared a post on X: "Hot off…
Apr 12, 2024, 11:46 |
Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Oct 23, 2023, 15:35 |
Blog
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA…
Oct 18, 2023, 16:51 |
Blog
Patrick Forde: ALINA adjuvant alectinib vs chemo for ALK post resected lung cancer
Quoting Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer…
All:
14
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube